AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies

Merck is favored over AstraZeneca, with Keytruda projected to reach $35 billion in peak sales by 2028 and new launches, pipeline progress and acquisitions positioned to cushion its subsequent loss of exclusivity. AstraZeneca targets $80 billion of 2030 revenue and 2026 CER revenue growth in the mid-to-high single digits, but its 2026 EPS consensus has fallen to $9.34 from $10.22 in 60 days amid pipeline setbacks, generic competition and China-related pressure. Merck shares are up 39.5% year-to-date versus AstraZeneca down 9.7%, although MRK trades at a richer 18.80x forward P/E versus AZN's 16.27x.

Analysis

The actionable signal is valuation asymmetry rather than near-term fundamental surprise: MRK is being priced as though its business-development program can bridge a concentrated 2028-29 immuno-oncology revenue cliff, while AZN is being discounted for risks that are already visible in estimates and its multiple. MRK's premium leaves little tolerance for a slower ramp in Winrevair/Welireg/Capvaxive or further vaccine weakness; AZN's lower multiple provides a more favorable setup if even one late-stage oncology asset restores confidence over the next 6-18 months.

A long AZN/short MRK relative-value position also isolates the divergent patent-risk profiles. MRK's challenge is a discrete, very large loss-of-exclusivity event that will increasingly enter valuation models during 2027; AZN has more distributed erosion and a broader set of launch opportunities, making its earnings stream less binary. The market may be underpricing the cost required for MRK to replace lost Keytruda economics—acquisitions can protect revenue but often dilute returns through high deal multiples and integration-related R&D expense.

Near term, avoid treating the positive melanoma combination readout as fully transferable to MRNA economics: commercial terms, regulatory path, manufacturing capacity and reimbursement remain the missing variables. The cleaner second-order beneficiary is TERN only if the acquired oncology program validates clinically and Merck's acquisition appetite re-rates comparable small-cap oncology assets; this is an event-driven watch, not a core position.

Falsification for the pair is an AZN guidance cut or further material pipeline failure, particularly if it forces 2027-28 consensus EPS lower again. Conversely, close or reverse if MRK demonstrates that new-product growth offsets both vaccine pressure and legacy-product erosion before 2027, or if Keytruda loss-of-exclusivity timing is legally extended.

Key Decisions for Investors

• Initiate a 6-12 month market-neutral long AZN / short MRK pair, sized beta-neutral. Target 10-15% relative outperformance from AZN multiple normalization and MRK de-rating toward its historical valuation; stop if AZN suffers another material Phase III failure or cuts its medium-term revenue framework.
• Do not chase MRK outright after its strong relative performance. Use any 5-8% further rally without upward revisions to ex-Keytruda revenue as an opportunity to add the MRK short leg; upside risk is faster-than-expected Winrevair uptake or a value-accretive acquisition.
• Maintain MRNA as a small, catalyst-driven watch position rather than a recommendation until the companies disclose recurrence-risk benefit magnitude, durability, safety, regulatory timing and commercialization economics. A favorable detailed dataset can justify upside exposure into filing; weak subgroup durability would remove the thesis.
• Monitor TERN and CDTX as oncology-M&A optionality screens over 6-18 months, but require clinical validation and a takeout premium that is not already embedded in enterprise value before initiating. Merck's need for post-2028 assets raises sector bid support, but does not make every oncology platform investable.